Endometrial stromal sarcoma

Treatment and patterns of recurrence

M. Bijoy Thomas, Gary Keeney, Karl C. Podratz, Sean Christopher Dowdy

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Our objective was to investigate recurrence patterns and conduct an outcome analysis of patients with endometrial stromal sarcoma (ESS). A retrospective review yielded 30 patients with ESS (20 low-grade, 10 high-grade) who underwent primary surgical resection from 1982 to 2005. Median follow-up was 42 months. All patients underwent hysterectomy, whereas pelvic (P) and paraaortic (PA) lymphadenectomy were performed in 12 and 7 patients, respectively. A median of 26 pelvic lymph nodes and 9 PA lymph nodes were removed. Pelvic or PA lymphatic disease was noted in 25% and 29% of patients, respectively. Extrauterine disease was identified in 11 (45%) of 24 patients undergoing exploratory laparotomy; 6 had no residual disease after cytoreductive surgery. None of these 6 patients experienced abdominal failure, but 1 had a hematological recurrence. Thrombotic complications were noted in 13% of patients. The 5-year overall survival was 65%. Overall survival was influenced by grade (79% vs 40%, P = 0.03) and extrauterine disease (77% vs 32%, P = 0.01). No patient who underwent a systematic lymphadenectomy had a lymphatic recurrence, irrespective of nodal status. There were 7 (23%) hematological recurrences; 2 in surgical stage I ESS. Two patients with low-grade ESS remain without evidence of disease 130 and 210 months after secondary cytoreduction. In contrast, no patient with high-grade ESS survived a recurrence. There is high prevalence of extrauterine and nodal disease in ESS. Patients are at high risk for thrombotic complications. If aggressively staged, the predominant failure risk for stage I patients is hematogenous, suggesting the need for improved systemic treatments.

Original languageEnglish (US)
Pages (from-to)253-256
Number of pages4
JournalInternational Journal of Gynecological Cancer
Volume19
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Endometrial Stromal Sarcoma
Recurrence
Therapeutics
Endometrial Stromal Tumors
Lymph Node Excision
Lymph Nodes
Survival
Lymphatic Diseases
Hysterectomy

Keywords

  • Endometrial stromal sarcoma
  • Lymphadenectomy
  • Surgical management

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology
  • Oncology

Cite this

Endometrial stromal sarcoma : Treatment and patterns of recurrence. / Thomas, M. Bijoy; Keeney, Gary; Podratz, Karl C.; Dowdy, Sean Christopher.

In: International Journal of Gynecological Cancer, Vol. 19, No. 2, 02.2009, p. 253-256.

Research output: Contribution to journalArticle

@article{2ffba4075134416fba1df8721ffccdf5,
title = "Endometrial stromal sarcoma: Treatment and patterns of recurrence",
abstract = "Our objective was to investigate recurrence patterns and conduct an outcome analysis of patients with endometrial stromal sarcoma (ESS). A retrospective review yielded 30 patients with ESS (20 low-grade, 10 high-grade) who underwent primary surgical resection from 1982 to 2005. Median follow-up was 42 months. All patients underwent hysterectomy, whereas pelvic (P) and paraaortic (PA) lymphadenectomy were performed in 12 and 7 patients, respectively. A median of 26 pelvic lymph nodes and 9 PA lymph nodes were removed. Pelvic or PA lymphatic disease was noted in 25{\%} and 29{\%} of patients, respectively. Extrauterine disease was identified in 11 (45{\%}) of 24 patients undergoing exploratory laparotomy; 6 had no residual disease after cytoreductive surgery. None of these 6 patients experienced abdominal failure, but 1 had a hematological recurrence. Thrombotic complications were noted in 13{\%} of patients. The 5-year overall survival was 65{\%}. Overall survival was influenced by grade (79{\%} vs 40{\%}, P = 0.03) and extrauterine disease (77{\%} vs 32{\%}, P = 0.01). No patient who underwent a systematic lymphadenectomy had a lymphatic recurrence, irrespective of nodal status. There were 7 (23{\%}) hematological recurrences; 2 in surgical stage I ESS. Two patients with low-grade ESS remain without evidence of disease 130 and 210 months after secondary cytoreduction. In contrast, no patient with high-grade ESS survived a recurrence. There is high prevalence of extrauterine and nodal disease in ESS. Patients are at high risk for thrombotic complications. If aggressively staged, the predominant failure risk for stage I patients is hematogenous, suggesting the need for improved systemic treatments.",
keywords = "Endometrial stromal sarcoma, Lymphadenectomy, Surgical management",
author = "Thomas, {M. Bijoy} and Gary Keeney and Podratz, {Karl C.} and Dowdy, {Sean Christopher}",
year = "2009",
month = "2",
doi = "10.1111/IGC.0b013e3181999c5f",
language = "English (US)",
volume = "19",
pages = "253--256",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Wolters Kluwer Health",
number = "2",

}

TY - JOUR

T1 - Endometrial stromal sarcoma

T2 - Treatment and patterns of recurrence

AU - Thomas, M. Bijoy

AU - Keeney, Gary

AU - Podratz, Karl C.

AU - Dowdy, Sean Christopher

PY - 2009/2

Y1 - 2009/2

N2 - Our objective was to investigate recurrence patterns and conduct an outcome analysis of patients with endometrial stromal sarcoma (ESS). A retrospective review yielded 30 patients with ESS (20 low-grade, 10 high-grade) who underwent primary surgical resection from 1982 to 2005. Median follow-up was 42 months. All patients underwent hysterectomy, whereas pelvic (P) and paraaortic (PA) lymphadenectomy were performed in 12 and 7 patients, respectively. A median of 26 pelvic lymph nodes and 9 PA lymph nodes were removed. Pelvic or PA lymphatic disease was noted in 25% and 29% of patients, respectively. Extrauterine disease was identified in 11 (45%) of 24 patients undergoing exploratory laparotomy; 6 had no residual disease after cytoreductive surgery. None of these 6 patients experienced abdominal failure, but 1 had a hematological recurrence. Thrombotic complications were noted in 13% of patients. The 5-year overall survival was 65%. Overall survival was influenced by grade (79% vs 40%, P = 0.03) and extrauterine disease (77% vs 32%, P = 0.01). No patient who underwent a systematic lymphadenectomy had a lymphatic recurrence, irrespective of nodal status. There were 7 (23%) hematological recurrences; 2 in surgical stage I ESS. Two patients with low-grade ESS remain without evidence of disease 130 and 210 months after secondary cytoreduction. In contrast, no patient with high-grade ESS survived a recurrence. There is high prevalence of extrauterine and nodal disease in ESS. Patients are at high risk for thrombotic complications. If aggressively staged, the predominant failure risk for stage I patients is hematogenous, suggesting the need for improved systemic treatments.

AB - Our objective was to investigate recurrence patterns and conduct an outcome analysis of patients with endometrial stromal sarcoma (ESS). A retrospective review yielded 30 patients with ESS (20 low-grade, 10 high-grade) who underwent primary surgical resection from 1982 to 2005. Median follow-up was 42 months. All patients underwent hysterectomy, whereas pelvic (P) and paraaortic (PA) lymphadenectomy were performed in 12 and 7 patients, respectively. A median of 26 pelvic lymph nodes and 9 PA lymph nodes were removed. Pelvic or PA lymphatic disease was noted in 25% and 29% of patients, respectively. Extrauterine disease was identified in 11 (45%) of 24 patients undergoing exploratory laparotomy; 6 had no residual disease after cytoreductive surgery. None of these 6 patients experienced abdominal failure, but 1 had a hematological recurrence. Thrombotic complications were noted in 13% of patients. The 5-year overall survival was 65%. Overall survival was influenced by grade (79% vs 40%, P = 0.03) and extrauterine disease (77% vs 32%, P = 0.01). No patient who underwent a systematic lymphadenectomy had a lymphatic recurrence, irrespective of nodal status. There were 7 (23%) hematological recurrences; 2 in surgical stage I ESS. Two patients with low-grade ESS remain without evidence of disease 130 and 210 months after secondary cytoreduction. In contrast, no patient with high-grade ESS survived a recurrence. There is high prevalence of extrauterine and nodal disease in ESS. Patients are at high risk for thrombotic complications. If aggressively staged, the predominant failure risk for stage I patients is hematogenous, suggesting the need for improved systemic treatments.

KW - Endometrial stromal sarcoma

KW - Lymphadenectomy

KW - Surgical management

UR - http://www.scopus.com/inward/record.url?scp=65649100480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649100480&partnerID=8YFLogxK

U2 - 10.1111/IGC.0b013e3181999c5f

DO - 10.1111/IGC.0b013e3181999c5f

M3 - Article

VL - 19

SP - 253

EP - 256

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 2

ER -